A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Background:

• The digestive tract is a frequent site for extranodal diffuse large B cell lymphoma (DLBCL).
• Prognostic evaluation for gastrointestinal DLBCL (GI-DLBCL) differs from other DLBCL types.
• Current staging systems (Ann Arbor, Lugano, TNM) lack a specific prognostic model for localized GI-DLBCL.

Purpose of the Study:

• To develop and validate a prognostic model for patients with GI-DLBCL.
• To identify a reliable tool for predicting poor prognosis in localized GI-DLBCL.

Main Methods:

• A cohort of 82 GI-DLBCL patients with a median follow-up of 75 months was analyzed.
• The HLAMA model was developed using hemoglobin, age, lactate dehydrogenase (LDH), serum albumin, and maximum intra-abdominal lesion diameter (MIALD).
• A simplified model using hemoglobin, LDH, and age was also created.

Main Results:

• Both the HLAMA and simplified models demonstrated significant prognostic ability (P<0.001).
• These models outperformed the International Prognostic Index (IPI) score, especially in distinguishing low-risk elderly patients (60-75 years).
• The models effectively identified high-risk patients with localized GI-DLBCL.

Conclusions:

• The study established a novel prognostic model (HLAMA) for GI-DLBCL.
• Both HLAMA and its simplified version offer a more accurate and simpler prognostic assessment compared to the IPI score.
• These models are valuable for risk stratification in GI-DLBCL patients.